Quotient Sciences Quotient Sciences

X
[{"orgOrder":0,"company":"Elysium Health","sponsor":"University of Oxford","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Elysium Health\u2122 Announces Research Partnership with the University of Oxford for the Purpose of Developing Epigenetic Measures of Brain Aging and Health","therapeuticArea":"Neurology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","url1":"","url2":"","graph1":"Neurology","graph2":"Undisclosed"}]

Find Clinical Drug Pipeline Developments & Deals by Elysium Health

Menu
Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Therapeutic Area
          filter Study Phase

            Active Filter(s):

            Companies By Therapeutic Area

            Development Status

            Details:

            Developing Elysium Health's proprietary algorithmic platform for epigenetic examination (APEX), and the company's biological age measure Index, Elysium Health plans to utilize the VITACOG biobank to explore the development and commercialization of novel brain health measures.

            Lead Product(s): Micronutrient-based Dietary Supplement

            Therapeutic Area: Neurology Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Small molecule

            Partner/Sponsor/Collaborator: University of Oxford

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Partnership March 23, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY